Clinical Trial Update: Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients [Phase 3]

View source ↗

Summary

A Phase 3 long-term study of certolizumab pegol added to methotrexate in Japanese rheumatoid arthritis patients has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CIMZIA (CERTOLIZUMAB PEGOL)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2014-09-17